SG11201908919XA - Combination therapies targeting pd-1, tim-3, and lag-3 - Google Patents
Combination therapies targeting pd-1, tim-3, and lag-3Info
- Publication number
- SG11201908919XA SG11201908919XA SG11201908919XA SG11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- tim
- lag
- applicant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Memory System Of A Hierarchy Structure (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo HE ollimoino oimIE (10) International Publication Number WO 2018/185232 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/058752 (22) International Filing Date: 05 April 2018 (05.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/481,973 05 April 2017 (05.04.2017) US (71) Applicant: SYMPHOGEN A/S [DK/DK]; Pederstrupvej 93, 2750 Ballerup (DK). (72) Inventors: LINDSTED, Trine; Hyldevwnget 13, 3520 Farum (DK). GRANDAL, Michael Monrad; Solbrinken 26a, 2750 Ballerup (DK). MELANDER, Eva Maria Carlsen; Ostra Hyllievagen 111, 216 23 Malmo (SE). FROHLICH, Camilla; Nojsomhedsvej 13, 2. th, 2100 Kobenhavn 0 (DK). PEDERSEN, Mikkel Wandahl; Forelvej 17, 3450 Alleroed (DK). KRAGH, Michael; Lwssoesgade 1A, 5. Tv., 2200 Copenhagen N (DK). LANTTO, Johan; Bryggaregaten 4, 227 36 Lund (SE). GAD, Monika; Gravenstensvej 8, 3450 Allerod (DK). HO- RAK, Ivan David; Rundholtsvej 26, 2300 Copenhagen S (DK). (74) Agent: POHLMAN, Sandra; TheatinerstraBe 16, 80333 Mfinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) ot CO (54) Title: COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3 1-1 0 (57) : This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies \" specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in 0 the therapies. The therapies are useful in treating diseases such as cancers.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762481973P | 2017-04-05 | 2017-04-05 | |
| PCT/EP2018/058752 WO2018185232A1 (en) | 2017-04-05 | 2018-04-05 | Combination therapies targeting pd-1, tim-3, and lag-3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908919XA true SG11201908919XA (en) | 2019-10-30 |
Family
ID=62027945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912941PA SG10201912941PA (en) | 2017-04-05 | 2018-04-05 | Combination therapies targeting pd-1, tim-3, and lag-3 |
| SG11201908919X SG11201908919XA (en) | 2017-04-05 | 2018-04-05 | Combination therapies targeting pd-1, tim-3, and lag-3 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912941PA SG10201912941PA (en) | 2017-04-05 | 2018-04-05 | Combination therapies targeting pd-1, tim-3, and lag-3 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11939380B2 (en) |
| EP (3) | EP4230654A1 (en) |
| JP (3) | JP2020513009A (en) |
| KR (2) | KR20190137105A (en) |
| CN (2) | CN110621698B (en) |
| AU (2) | AU2018247916A1 (en) |
| BR (1) | BR112019020662A2 (en) |
| CA (2) | CA3185303A1 (en) |
| CL (2) | CL2019002850A1 (en) |
| CO (1) | CO2019012080A2 (en) |
| EA (1) | EA201992350A1 (en) |
| IL (1) | IL269644A (en) |
| MA (1) | MA49042A (en) |
| MX (2) | MX2019011961A (en) |
| PE (1) | PE20191741A1 (en) |
| PH (1) | PH12019502191A1 (en) |
| SG (2) | SG10201912941PA (en) |
| TW (2) | TWI822101B (en) |
| WO (1) | WO2018185232A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| TN2018000333A1 (en) | 2016-04-12 | 2020-01-16 | Symphogen As | Anti-tim-3 antibodies and compositions |
| CN117683135A (en) | 2016-07-14 | 2024-03-12 | 百时美施贵宝公司 | Antibodies against TIM3 and uses thereof |
| MX2019003683A (en) | 2016-10-11 | 2019-08-22 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof. |
| PE20190911A1 (en) | 2016-10-13 | 2019-06-26 | Symphogen As | ANTI-LAG-3 COMPOSITIONS AND ANTIBODIES |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| JP6997212B2 (en) | 2017-04-05 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antibodies that specifically bind to PD1 and LAG3 |
| EP4230654A1 (en) * | 2017-04-05 | 2023-08-23 | Symphogen A/S | Combination therapies targeting pd-1, tim-3, and lag-3 |
| US10894833B2 (en) * | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| EP3737700A1 (en) | 2018-01-12 | 2020-11-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| CN111253485A (en) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | Anti-human TIM-3 monoclonal antibody and application thereof |
| CN113825527A (en) * | 2019-05-13 | 2021-12-21 | 瑞泽恩制药公司 | Combination of a PD-1 inhibitor and a LAG-3 inhibitor for enhanced efficacy in the treatment of cancer |
| CN113214396B (en) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | Single-chain antibody of anti-TIM 3 and application thereof in preparing medicine for treating tumor |
| CN112812179B (en) * | 2021-01-19 | 2022-07-22 | 北京大学 | High-affinity high-specificity anti-CMTM 6 monoclonal antibody and application thereof |
| WO2023240082A2 (en) * | 2022-06-07 | 2023-12-14 | Incyte Corporation | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer |
| WO2024041652A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment |
| WO2024041651A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies |
| WO2024051670A1 (en) * | 2022-09-06 | 2024-03-14 | 正大天晴药业集团股份有限公司 | Pharmaceutical combination of antibody binding to tim-3 and antibody binding to pd-1 |
| WO2024183643A1 (en) * | 2023-03-03 | 2024-09-12 | 正大天晴药业集团南京顺欣制药有限公司 | Pharmaceutical combination containing anti-tim-3 antibody |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| AU584417B2 (en) | 1985-04-01 | 1989-05-25 | Lonza Group Ag | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| RU2178306C2 (en) | 1994-05-06 | 2002-01-20 | Энститю Гюстав Русси | Soluble polypeptide fraction of protein lag-3, method of preparing, therapeutical composition, antibody |
| US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
| HUP0300369A2 (en) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| DK1583830T3 (en) | 2003-01-07 | 2007-01-15 | Symphogen As | Process for Preparation of Recombinant Polyclonal Proteins |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| EP2161336B2 (en) | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR101105610B1 (en) | 2006-08-17 | 2012-01-18 | 에프. 호프만-라 로슈 아게 | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| NZ581316A (en) | 2007-05-25 | 2012-02-24 | Symphogen As | Method for manufacturing a recombinant polyclonal protein |
| ES2616355T3 (en) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Antibodies for the human programmed death receptor PD-1 |
| EP2252319A2 (en) | 2008-01-29 | 2010-11-24 | The Brigham and Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| CA2722348A1 (en) | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| WO2010040356A1 (en) | 2008-10-06 | 2010-04-15 | Symphogen A/S | Method for identifying and selecting drug candidates for combinatorial drug products |
| WO2010084999A1 (en) | 2009-01-26 | 2010-07-29 | Protegene, Inc. | Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| EP2417984B1 (en) | 2009-04-10 | 2016-03-30 | Kyowa Hakko Kirin Co., Ltd. | Method for treatment of blood tumor using anti-tim-3 antibody |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2581113B1 (en) | 2010-06-11 | 2018-05-09 | Kyowa Hakko Kirin Co., Ltd. | Anti-tim-3 antibody |
| JP2013532153A (en) * | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | Bispecific antibodies against TIM-3 and PD-1 for immunotherapy against chronic immune disease |
| EP3156421B1 (en) | 2010-11-01 | 2018-06-06 | Symphogen A/S | Pan-her antibody composition |
| JP6014116B2 (en) | 2011-03-31 | 2016-10-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| KR101933990B1 (en) | 2012-05-02 | 2018-12-31 | 심포젠 에이/에스 | Humanized pan-her antibody compositions |
| UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| JP2016508504A (en) | 2013-02-01 | 2016-03-22 | サンタ マリア バイオセラピューティクス インコーポレイテッド | Administration of anti-activin-A compound to a subject |
| AU2014230741B2 (en) | 2013-03-15 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding proteins |
| CN104250302B (en) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | The anti-antibody of PD 1 and its application |
| PT3702373T (en) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| LT3508502T (en) | 2013-09-20 | 2023-07-10 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JP6502959B2 (en) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | PD-1 antibodies, antigen binding fragments thereof and their medical use |
| WO2015175340A1 (en) * | 2014-05-13 | 2015-11-19 | Bavarian Nordic, Inc. | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
| CN103936853B (en) | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | A kind of detection TIM-3 test kit and using method thereof |
| JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
| RU2690670C2 (en) | 2014-03-12 | 2019-06-05 | Ида Рисерч Энд Дивелопмент Ко., Лтд | Reduced levels or activity of systemic regulatory t cells for treating disease or cns injury |
| UY36032A (en) | 2014-03-14 | 2015-10-30 | Novartis Ag | ANTIBODY MOLECULES THAT JOIN LAG-3 AND USES OF THE SAME |
| AU2015292678B2 (en) | 2014-07-22 | 2020-10-22 | Cb Therapeutics, Inc. | Anti-PD-1 antibodies |
| JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
| TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
| EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| MA41463A (en) * | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) |
| JP2018510151A (en) | 2015-03-06 | 2018-04-12 | ソレント・セラピューティクス・インコーポレイテッド | Antibody drug binding to TIM3 |
| TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| EP3337826A1 (en) | 2015-08-20 | 2018-06-27 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| EP4105235A1 (en) * | 2015-10-02 | 2022-12-21 | Symphogen A/S | Anti-pd-1 antibodies and compositions |
| KR102431342B1 (en) | 2015-10-02 | 2022-08-10 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies specific for pd1 and tim3 |
| TN2018000333A1 (en) | 2016-04-12 | 2020-01-16 | Symphogen As | Anti-tim-3 antibodies and compositions |
| SI3458478T1 (en) * | 2016-05-18 | 2021-04-30 | Boehringer Ingelheim International Gmbh | Anti pd-1 and anti-lag3 antibodies for cancer treatment |
| CN117683135A (en) | 2016-07-14 | 2024-03-12 | 百时美施贵宝公司 | Antibodies against TIM3 and uses thereof |
| JOP20190013A1 (en) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | Anti-tim-3 antibodies |
| PE20190911A1 (en) | 2016-10-13 | 2019-06-26 | Symphogen As | ANTI-LAG-3 COMPOSITIONS AND ANTIBODIES |
| EP3541841B1 (en) | 2016-11-18 | 2024-09-11 | Les Laboratoires Servier | Anti-pd-1 antibodies and compositions |
| JOP20190133A1 (en) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies |
| EP4230654A1 (en) * | 2017-04-05 | 2023-08-23 | Symphogen A/S | Combination therapies targeting pd-1, tim-3, and lag-3 |
| JOP20190222A1 (en) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | Anti-pd-l1-anti-tim-3 bispecific antibodies |
-
2018
- 2018-04-05 EP EP23161859.6A patent/EP4230654A1/en active Pending
- 2018-04-05 KR KR1020197030876A patent/KR20190137105A/en not_active Application Discontinuation
- 2018-04-05 SG SG10201912941PA patent/SG10201912941PA/en unknown
- 2018-04-05 CA CA3185303A patent/CA3185303A1/en active Pending
- 2018-04-05 EP EP22177869.9A patent/EP4116328A1/en active Pending
- 2018-04-05 AU AU2018247916A patent/AU2018247916A1/en active Pending
- 2018-04-05 MA MA049042A patent/MA49042A/en unknown
- 2018-04-05 SG SG11201908919X patent/SG11201908919XA/en unknown
- 2018-04-05 US US16/500,918 patent/US11939380B2/en active Active
- 2018-04-05 PE PE2019001998A patent/PE20191741A1/en unknown
- 2018-04-05 CN CN201880032633.7A patent/CN110621698B/en active Active
- 2018-04-05 MX MX2019011961A patent/MX2019011961A/en unknown
- 2018-04-05 BR BR112019020662A patent/BR112019020662A2/en unknown
- 2018-04-05 CN CN202210655817.7A patent/CN114984209A/en active Pending
- 2018-04-05 EA EA201992350A patent/EA201992350A1/en unknown
- 2018-04-05 KR KR1020227019731A patent/KR20220083863A/en not_active Application Discontinuation
- 2018-04-05 WO PCT/EP2018/058752 patent/WO2018185232A1/en active Application Filing
- 2018-04-05 JP JP2019554785A patent/JP2020513009A/en active Pending
- 2018-04-05 EP EP18719068.1A patent/EP3606957A1/en active Pending
- 2018-04-05 CA CA3058960A patent/CA3058960C/en active Active
- 2018-04-09 TW TW111121455A patent/TWI822101B/en active
- 2018-04-09 TW TW107112114A patent/TWI801376B/en active
-
2019
- 2019-09-24 PH PH12019502191A patent/PH12019502191A1/en unknown
- 2019-09-25 IL IL26964419A patent/IL269644A/en unknown
- 2019-10-04 CL CL2019002850A patent/CL2019002850A1/en unknown
- 2019-10-04 MX MX2022007140A patent/MX2022007140A/en unknown
- 2019-10-29 CO CONC2019/0012080A patent/CO2019012080A2/en unknown
-
2021
- 2021-12-01 CL CL2021003196A patent/CL2021003196A1/en unknown
-
2022
- 2022-06-07 US US17/834,554 patent/US20220380470A1/en active Pending
- 2022-06-09 JP JP2022093937A patent/JP7523491B2/en active Active
- 2022-06-10 AU AU2022204078A patent/AU2022204078A1/en active Pending
-
2023
- 2023-11-02 JP JP2023188380A patent/JP2024023222A/en active Pending
-
2024
- 2024-02-16 US US18/444,187 patent/US20240270848A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201903737PA (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201906557UA (en) | Novel stable formulation for fxia antibodies | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |